REGN

Regeneron Pharmaceuticals and Sanofi's drug Dupixent showed successful treatment of patients with chronic spontaneous urticaria and bullous pemphigoid, two inflammatory skin diseases, in Phase 3 trials.

Regeneron presented new analyses of EYLEA HD and EYLEA at the EURETINA meeting, highlighting the long-term efficacy, safety, and extended dosing intervals of these treatments for wet age-related macular degeneration and diabetic macular edema.

The article discusses Eli Lilly and Regeneron Pharmaceuticals as potential stock split candidates due to their strong business performance and high share prices. It suggests that these companies could see their share prices continue to rise, making a stock split a likely possibility in the near futu...

A Dupixent (dupilumab) confirmatory phase 3 study met the primary and key secondary endpoints for the treatment of patients with uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) receiving background therapy with antihistamines. The study showed clinically meaningful reductions in itc...

Dupixent, a drug developed by Sanofi and Regeneron, has met its primary and key secondary endpoints in a Phase III study for the treatment of chronic spontaneous urticaria (CSU). The study showed Dupixent reduced pruritus and urticaria scores by nearly 50% compared to placebo in patients with inadeq...